Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin

Muthu Veeraputhiran, Mark Sundermeyer

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Erlotinib is an epidermal growth factor receptor inhibitor indicated as a second line of therapy for locally advanced and metastatic non - small-cell lung cancer after the failure of 1 previous chemotherpy. Simvastatin belongs to the statin family used to lower blood cholesterol. Drug interaction between erlotinib and statin has not been reported before. Both drugs are major substrates of the CYP3A4 enzyme in the liver. Thus, co-administration of these drugs can increase their serum levels, potentially leading to adverse effects. We report the interaction between erlotinib and simvastatin leading to rhabdomyolysis. Thus, caution is required with increasing usage of both of these drugs.

Original languageEnglish
Pages (from-to)232-234
Number of pages3
JournalClinical Lung Cancer
Volume9
Issue number4
DOIs
StatePublished - Jul 2008

Keywords

  • CYP3A4
  • Drug interaction
  • Hepatotoxicity
  • Pravastatin

Fingerprint

Dive into the research topics of 'Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin'. Together they form a unique fingerprint.

Cite this